JPRN-jRCT2031210313招募中2 期
Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinoma - T-DXd_NAC
Shitara Kohei0 个研究点目标入组 37 人开始时间: 2021年9月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction.
- •2. Has HER2 overexpression (IHC3+, or IHC2+ and ISH positive [FISH or DISH]). (HER2 Low expression: IHC1+, or IHC2+ and ISH-negative [FISH or DISH] with HER2-ECD > 11.6 ng/mL in the exploratory cohort).
- •3. Have previously untreated gastric and gastroesophageal junction adenocarcinoma and cT2-4 and/or cN+M0.according to the UICC TNM classification (8th edition),
- •4. Age >= 20 years as the day of informed consent.
- •5. Has an ECOG performance status (PS) of 0 or 1.
- •6. Has a left ventricular ejection fraction (LVEF) >= 50% by either echocardiogram (ECHO) or multigated collecting acquisition (MUGA) scan within 28 days before enrollment (acceptable on the same day of the week).
- •7. Has a corrected QT interval (QTc) <= 470 ms in females, or QTc <= 450 ms in males based on a 12-lead ECG screening within 28 days before enrollment (allowed on the same day of the week). [Fridericia's correction is recommended]
- •8. Satisfies all of the following requirements within 14 days before enrollment (allowed on the same day of the week).
- •-Absolute neutrophil count >=1500 / mm3 [except for assessment <= 14 days after administration of Granules colony-stimulating factors (G-CSF)]
- •-Hemoglobin >= 8.0 g/dL (except for those measured within 7 days after whole blood transfusion or packed red blood cells)
- •-Platelet count >=100000 per mm3 (excluding measurements within 7 days after platelet transfusion).
- •-Total bilirubin <=1.5 mg/dL (patients with gilbert's syndrome will be allowed if they have < 3.0 mg/dL).
- •-AST(GOT)<=100 IU/L
- •-ALT(GPT)<=100 IU/L
- •-Serum albumin >= 2.5 g/dL
- •-Calculated creatinine clearance (Cockcroft-Gault *) or the actual value >= 30 mL/min
- •* Cockcroft-Gault equation: creatinine clearance= (140 - age) * body weight (kg) / (72 * Serum creatinine)
- •(* 0.85 x the value obtained for females).
- •-PT(INR)< 1.8
- •-aPTT < 60 seconds
- •9. Has a treatment-free period from the end of pre-treatment to before enrollment (allowed on the same day of the week), defined as:
- •i. Surgery with general anesthesia : >= 4 weeks
- •ii. Radiotherapy: >= 4 weeks (including palliative stereotactic body radiation therapy to the chest; palliative stereotactic body radiation therapy to other than the chest >= 2 weeks; abdominal vertebral bodies should be included in the abdomen).
- •iii. Chloroquine and hydroxychloroquine : >= 15 days
- •10. Has a prior radiotherapy or surgical AE recovered of <= Grade 1 or <= baseline on CTCAE v5.0. However, this shall not apply to events where the symptoms are stable even if they are grade 2 or higher.
- •11. Female of childbearing potential have a negative pregnancy test within 7 days before enrollment (allowed on the same day of the week). Male and Female of childbearing potential agree to contraception for a period (4 months for male and 7 months for Female) from informed consent to the last dose of study drug (see 4.3 Pregnancy and contraception).
- •12. Written informed consent of participation in the study has been obtained from the patient.
排除标准
- •1.Has a medical history/complication of myocardial infarction or congestive heart failure (New York Heart Association Classes II-IV) within 6 months before enrollment, corresponding to the value diagnosed as myocardial infarction as defined by the *manufacturer within 28 days before enrollment (allowed on the same day), unstable angina, or any serious arrhythmia requiring treatment.
- •*: Manufacturer refers to a testing company used by a study implementation institution.
- •**: Enrollment is allowed if a subject exceeds ULN, if the subject is examined and myocardial infarction can be excluded.
- •2.Active multiple cancers [Synchronous duplicate cancers and metachronous multiple cancers within 3 years prior to enrollment, but carcinoma in situ or other lesions corresponding to mucosal carcinoma that are considered curable with Local treatment will not be included in active multiple cancers.]
- •3.Has serious (hospitalized) complications (intestinal palsy, intestinal obstruction, pulmonary fibrosis, diabetes mellitus that is difficult to control, heart failure, myocardial infarction, unstable angina, renal failure, liver failure, psychiatric disorders, cerebrovascular disorders, etc.).
- •4.Has history of gastrointestinal perforation and/or gastrointestinal fistula within 6 months before enrollment.
- •5.Has any of the following infections:
- •-HBs antigen positive
- •-HBs antibody or HBc antibody and HBV-DNA positive
- •-Active hepatitis C (eg, if HCV RNA is detected qualitatively)
- •Patients who are HBsAg positive but who have achieved HBV DNA level < 1.3 log IU/mL (2.1 log copies/mL) after treatment with antiviral drugs such as NAs, are eligible for the study.
- •6.HIV infection has been documented.
- •7.Lung diseases are defined as:
- •-Has a history of non-infectious interstitial lung disease or pneumonitis that required treatment, has interstitial lung disease or pneumonitis, or these lung diseases cannot be ruled out by radiographic examination before enrollment.
- •-Severe pulmonary impairment (eg, pulmonary embolism within 3 months prior to enrollment, serious bronchial asthma, severe COPD, restrictive pulmonary disease, or pleural effusion).
- •Lung-related autoimmune or connective tissue or inflammatory diseases (eg, rheumatoid arthritis, Sjogren's syndrome, or sarcoidosis) with clinically severe pulmonary risks.
- •Has history of pneumonectomy.
- •8.Has history of concomitant autoimmune disease or chronic or recurrent autoimmune disease.
- •9.Administration of systemic adrenocortical hormones (except prophylactic administration for tests or allergic reactions, and temporary use for the purpose of reducing edema associated with radiotherapy) or immunosuppressants is required, or has received these treatments within 14 days before enrollment in the study.
- •10.Has unhealed wounds, ulcers, or fractures.
- •11.If patients are a pregnancy or breastfeeding patient.
- •12.Has documented severe hypersensitivity to study drug active ingredients or additives.
- •13.Has history/complications of severe hypersensitivity reactions to other monoclonal antibodies.
- •14.If you have uncontrolled acute systemic infection that requires Infusion intravenous antibiotic, antiviral, or antifungal drug.
- •15.Unwilling or unable to comply with any of implementation matters stipulated in the study implementation protocol or any of the instructions of the physician.
- •16.The investigator or subinvestigator considered it ineligible for the study.
研究者
相似试验
进行中（未招募）
1 期
Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain MetastasesHER2-positive Breast Cancer with newly diagnosed or progressing Brain MetastasesEUCTR2020-000981-41-ATMed. Univ. Wien, Klinik f. Innere Mdizin I, Onkologie15
招募中
1 期
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing Brain Metastases. (The TUXEDO-4 Study)HER2-low breast cancer presenting with newly diagnosed or progressing brain metastases with or without type II leptomeningeal disease.CTIS2023-506702-39-00Medica Scientia Innovation Research S.L.27
已完成
2 期
DESTINY-Lung01JPRN-jRCT2080223860DAIICHI SANKYO Co.,Ltd.170
招募中
1 期
Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients considered resistant to trastuzumab + pertuzumab + taxane due to early relapse. TRANSCENDER Study”MedDRA version: 23.0Level: PTClassification code: 10065430Term: HER2 positive breast cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104Metastatic breast cancerCTIS2023-503627-26-00Grupo Espanol De Investigacion En Cancer De Mama41
进行中（未招募）
1 期
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive, Metastatic Breast CancerHER2-positive metastatic breast cancerMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004074-21-ESAstraZeneca AB1,134